SCHEMBL23797939

SCHEMBL23797939

CC(C)(C)OC(=O)N1Cc2ccc(Oc3ccc([N+](=O)[O-])cn3)cc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSPB1 P04792 1/20 0.46
▸ MAPT P10636 4/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ LMNA P02545 3/20 0.45
▸ ESR2 Q92731 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ NR1H2 P55055 1/20 0.43
▸ LIPE Q05469 2/20 0.42
▸ GAA P10253 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ HDAC1 Q13547 1/20 0.41
▸ HPGD P15428 1/20 0.40
▸ ACACB O00763 1/20 0.40
▸ OPRM1 P35372 2/20 0.40
▸ PPARG P37231 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23797930 0.83 NR1H2 (0.54) ALDH1A1ESR2RAB9ANR1H2LIPE
SCHEMBL1393643 0.81 ALDH1A1 (0.57) MAPTALDH1A1LMNAESR2MAPK1
SCHEMBL31013917 0.80 GPR119 (0.47) ESR2MAPK1NR1H2LIPEHDAC1
SCHEMBL23797938 0.79 HSPB1 (0.47) HSPB1MAPTNPSR1ALDH1A1LMNA
SCHEMBL3142046 0.78 MGLL (0.56) HSPB1MAPTNPSR1ALDH1A1LMNA
SCHEMBL3047375 0.77 MAPT (0.45) HSPB1MAPTNPSR1ALDH1A1LMNA
SCHEMBL3056799 0.77 ALDH1A1 (0.45) MAPTALDH1A1LMNAMAPK1HTT
SCHEMBL3058743 0.77 HRH4 (0.53) MAPTALDH1A1LMNAOPRM1
SCHEMBL3063307 0.77 HSPB1 (0.39) HSPB1MAPTNPSR1ALDH1A1LMNA
SCHEMBL3693963 0.77 OPRM1 (0.62) ESR2OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415816-B2 Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-09-16 — — US disclosed
US-20230148448-A9 BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-20230148448-A9 BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-20220127284-A1 BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF GRAY NATHANAEL S (US) 2022-04-28 — — US disclosed
EP-3876939-A1 BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF Dana-Farber Cancer Institute, Inc. (US) 2021-09-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415816-B2 Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof JAK2, JAK1, JAK3 HSPB1 3971/4885MAPT 283/4885NPSR1 3691/4885
US-20230148448-A9 BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF JAK2, JAK1, JAK3 HSPB1 3971/4885MAPT 283/4885NPSR1 3691/4885
US-20220127284-A1 BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF JAK2, JAK1, JAK3 HSPB1 3971/4885MAPT 283/4885NPSR1 3691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback